Don't let R&D expenses derail your High-Tech Enterprise application! These 8 pitfalls trip up applicants every year.
In recent years, high-tech enterprise (HNTE) regulatory oversight has tightened significantly. Data shows that the number of enterprises losing HNTE status from 2021 to 2025 was 889, 773, 1741, 4931, and 5453 respectively, with a sharp surge after 2024. According to HuaRui Audit's service data for 2025, 9% of failed HNTE applications were due to improper financial accounting treatment. The top three reasons for rejection are: incorrect R&D expense allocation, unclear recognition of high-tech product/service income, and unreasonable cost allocation for technical personnel.
Review the following 8 common pitfalls one by one.
Pitfall 1: Outsourced R&D expenses are fully collected without knowing the "80%" threshold.
Typical manifestation: The enterprise includes the full amount paid to external institutions for R&D in total R&D expenses.
Policy Basis: According to the "Guidelines for High-Tech Enterprise Certification Management" (Guo Ke Fa Huo [Year 2016] No. 195), expenses for outsourcing R&D should be counted toward the total R&D expenses of the commissioning party at 80% of the actual amount incurred. Some enterprises directly aggregate the full amount, artificially inflating R&D expenses and increasing the R&D investment ratio. This exposes them to risks including revocation of high-tech enterprise status, repayment of previously enjoyed corporate income tax incentives, and imposition of late payment penalties.
Compliance Key Points:
1. Outsourced R&D within China is recognized at 80% of actual expenses; for overseas outsourcing, the recognition rate is 80%, capped at two-thirds of eligible R&D expenses incurred in China.
2. Outsourced R&D contracts should be registered with the science and technology administration. Without proper registration and a complete chain of deliverable acceptance, outsourced expenses are highly susceptible to scrutiny during audits; 3. For outsourced R&D, maintain a complete evidence chain including service agreements, communication records, and acceptance reports.
Pitfall 2: Mixing R&D expenses with production costs; uncontrolled capitalization timing.
Typical manifestations: The same technical personnel performs both production tasks and R&D projects, with 100% of their compensation allocated to R&D expenses; R&D material requisitions are not linked to specific project numbers and are directly recorded as R&D expenditures.
Real-world case: A precision instrument company received an adverse opinion during its high-tech enterprise re-evaluation. An audit sample revealed that the same technician logged 230 hours of production work on manufacturing orders, yet their full salary was incorrectly classified as R&D expense. Additionally, 180 yuan worth of specialty alloy materials requisitioned during the prototype development phase were directly charged to R&D expenses without passing through the "Inventory-Prototype Products" account, blurring the boundary between expensed and capitalized R&D costs.
Compliance Key Points:
1. All R&D personnel must submit daily work hour reports in the OA system. At month-end, finance allocates salaries based on these hours; production-related hours are automatically reversed against production costs.
2. R&D material requisition must be linked to a specific R&D project number; the material delivery note requires dual signatures from the technical lead and warehouse supervisor.
3. Pilot unit costs are initially recorded under "Construction in Progress - Pilot Products." Upon issuance of the technical appraisal report, costs meeting capitalization criteria are transferred to Intangible Assets; otherwise, they are expensed in the current period.
Pitfall 3: Confused allocation of personnel costs; unclear timesheets
Typical issues include: recording 100% of all technical staff salaries as R&D expenses without timesheet records, or incorrectly allocating administrative and sales personnel salaries to R&D labor costs.
Allocating labor costs is a high-risk area prone to errors due to the complex interplay of personnel, hours, and projects. Six common pitfalls in practice are:
1. Unclear scope of personnel: Wages of non-R&D staff are included in R&D expenses.
2. Inaccurate time tracking: Engaging in both R&D and non-R&D activities simultaneously with arbitrary, unsupported time allocation. Unallocated hours are not eligible for additional deductions.
3 Mismatch between payroll collection period and project lifecycle: R&D expenses incorrectly include salaries for projects that have not yet been initiated or have already been closed.
4. Incomplete cost breakdown: Only base salary is included; bonuses, allowances, social security, and housing fund are missing.
5. Insufficient supporting documentation: Only a single payroll sheet is provided, lacking project initiation reports, timesheets, social security payment records, etc.
6. Confused with other expenses: Incorrectly classified travel expenses, employee welfare benefits, and supplementary pension insurance as personnel labor costs.
Compliance Essentials: Personnel must be "clear," hours must be "accurate," costs must be "complete," and evidence must be "sufficient." Establish a R&D timesheet to record employees' actual time spent on R&D projects. Timesheet records should align with attendance, project progress, and deliverables.
Pitfall 4: Incorrect calculation of the "Other Expenses" limit, leading to reduction due to exceeding the percentage cap.
Typical manifestation: Excessively classifying expenses such as communication, travel, and employee benefits into R&D costs, causing "Other Expenses" to exceed the limit.
There is a significant difference in the cap for "other expenses" between High-Tech Enterprise (HT) certification and R&D super deduction: under HT certification, other expenses must not exceed 20% of total R&D expenses; under the super deduction, the limit is 10%, with different calculation methodologies.
For additional deductions, the limit for other related expenses is calculated as: (Sum of personnel costs and four other expense categories across all R&D projects) × 10% ÷ (1 - 10%). When multiple R&D activities are conducted within a single tax year, the "other related expenses" limit must be calculated collectively for all projects, not separately for each one.
Compliance Note: Travel expenses, employee welfare costs, supplementary pension insurance, and supplementary medical insurance should be classified under "Other Related Expenses" rather than "Personnel and Labor Costs" to ensure full deductibility. Calculate the proportion of other expenses before each annual filing; adjust any excess amounts in advance if limits are exceeded.
Pitfall 5: Arbitrary allocation of shared equipment and personnel costs without reasonable justification
Typical issue: Equipment and facilities shared between R&D and production are not allocated based on actual usage (e.g., labor hours, floor area, or machine hours), leading to the full cost being incorrectly charged to R&D expenses.
Under review: Depreciation of shared equipment must be allocated based on the proportion of actual usage hours. Any portion lacking valid allocation basis cannot be added to the deduction. Some enterprises have incorrectly included daily operational electricity costs, such as lighting and air conditioning in office areas, as R&D expenses, or failed to reasonably allocate depreciation for equipment used in both R&D and non-R&D activities.
Compliance Key Points:
1. Establish a ledger for shared resource usage and allocate costs based on verifiable standards such as labor hours, machine hours, and area.
2. Depreciation of exclusive R&D equipment can be properly allocated; shared equipment with no R&D usage records shall not be allocated.
3. In months with no R&D activities, neither wages nor depreciation can be allocated.
Mistake 6: Failure to properly handle special revenues such as samples and scrap materials.
Typical issue: Proceeds from the sale of offcuts, defective products, and pilot samples generated during R&D are not properly deducted from R&D expenses as required.
For super deduction purposes, special income generated during R&D (e.g., scrap, defective products, or pilot samples) must be deducted from the accumulated R&D expenses. If the income exceeds the expenses, the deductible amount is zero.
Key Distinction: There is a discrepancy in how high-tech certification and super-deduction handle special income. For high-tech certification, the R&D expense base uses the total actual investment before deductions; only for super-deduction is the amount calculated after such deductions. Many companies incorrectly use the post-deduction figure from super-deduction for high-tech audits, leading to inaccurate R&D intensity ratios. Conversely, some directly apply amounts calculated under high-tech standards to super-deduction claims without deducting special income, resulting in inflated super-deductions.
Compliance Key Point: Calculate using two separate metrics; do not mix them. For prototype sales and scrap revenue, verify both whether they are deducted and whether they are included in total revenue. Including scrap revenue in total revenue reduces the proportion of high-tech product revenue. If the ratio was originally just meeting the 60% threshold, it may no longer satisfy the High-Tech Enterprise certification requirements.
Pitfall 7: R&D projects misclassified as "non-R&D activities"
Typical manifestation: Including non-R&D activities, such as routine upgrades and custom development, in R&D expenses.
In practice, certain projects involve routine upgrades to existing products without innovative technical breakthroughs, while others have incomplete R&D documentation; neither qualifies as R&D activity. Key verification focuses on five scenarios: 1) counting non-R&D activities such as routine upgrades or custom development as R&D; 2) mismatches between auxiliary R&D ledgers and project approvals or IP inventors; 3) unregistered outsourcing R&D contracts or unclear ownership of deliverables; 4) inconsistencies between financial statements and records; 5) other expenses exceeding the 20% cap.
Compliance Key Points: Clearly define technical innovation points at project initiation. Retain process documentation such as technical proposals, test records, and reports to ensure the project demonstrates clear innovation and technical uncertainty. Vague definitions of R&D activities and routine product upgrades are key focus areas during audits.
Pitfall 8: Misjudging capitalization timing leads to distorted R&D expense ratios.
Typical manifestation: All R&D expenditures are either expensed or capitalized without reasonable differentiation in accordance with applicable standards.
Case studies show that a biopharmaceutical company expensed all R&D expenditures of 420 million yuan during its application, leaving the R&D expense ratio just 0.3 percentage points below the required threshold. Misjudging the capitalization timing directly distorted total R&D expenses, which was the primary technical reason for the rejection.
According to Accounting Standards for Business Enterprises No. 6 — Intangible Assets, capitalization of research and development expenditures requires meeting all five criteria: technical feasibility, intent to complete and use or sell the asset, ability to use or sell the asset, reliable measurement of expenditures, and probability of future economic benefits. Companies may manipulate the timing of capitalization to capitalize ineligible costs in order to inflate profits, or expense all R&D costs to increase the R&D base; both practices trigger audit risks.
Compliance Key Points: Establish criteria for capitalizing R&D expenditures. At the point when an R&D project meets capitalization conditions, ensure timely documentation (e.g., technical appraisal reports, feasibility review records). The distinction between capitalized and expensed amounts must be clearly documented and auditable.
High-tech enterprise application is a systematic process, and R&D expense compliance runs throughout. We recommend that companies begin reviewing their R&D expenses at least 6-12 months before submission, systematically checking against the 8 common pitfalls listed above to ensure every R&D expense can withstand "punch-through" regulatory scrutiny.
If your company encounters specific issues during R&D expense aggregation or high-tech enterprise declaration, feel free to leave a message to discuss.